+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Zoonotic Disease Treatment Market - Global Forecast 2026-2032- Product Image
Zoonotic Disease Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Zoonotic Disease Treatment Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989949
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Zoonotic Disease Treatment Market is projected to reach USD 52.02 Billion in 2026. It is expected to continue growing at a CAGR of 9.12%, reaching USD 88.27 Billion by 2032.

Zoonotic disease treatment is moving from a reactive infectious disease category to a strategic One Health priority spanning human medicine, veterinary health, diagnostics, vaccines, antivirals, antimicrobials, immunotherapies, and surveillance-enabled care. The market is shaped by well-established epidemiological evidence: the WHO and CDC recognize that most known infectious diseases in people and a large share of emerging infectious diseases originate in animals, with spillover risks amplified by land-use change, livestock intensification, wildlife trade, climate variability, global travel, and urbanization.

Commercial demand is supported by recurring outbreaks of rabies, brucellosis, leptospirosis, avian influenza, dengue, chikungunya, plague, viral hemorrhagic fevers, and other zoonoses that require rapid diagnosis, appropriate therapeutics, post-exposure prophylaxis, infection control, and coordinated public health response. For industry leaders, the opportunity lies in building treatment portfolios that connect early detection, evidence-based clinical management, antimicrobial stewardship, vaccination, and animal-to-human risk reduction.

Transformative Shifts in the Treatment Landscape

The zoonotic disease treatment landscape is being transformed by the convergence of One Health policy, pandemic preparedness funding, genomic surveillance, and decentralized diagnostics. Governments and multilateral organizations are prioritizing integrated surveillance across humans, animals, food systems, and the environment, which is changing procurement requirements and encouraging solutions that can work across hospitals, laboratories, farms, and field-response settings.

Another major shift is the move from broad, empiric intervention toward pathogen-specific and resistance-aware treatment decisions. Antimicrobial resistance, vaccine hesitancy, cold-chain limitations, and uneven access to diagnostics are forcing manufacturers and healthcare systems to prove clinical value, operational feasibility, and cost-effectiveness. Organizations that pair therapies with rapid tests, real-world evidence, pharmacovigilance, and outbreak response services are better positioned to win institutional trust.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing zoonotic disease treatment by improving outbreak intelligence, differential diagnosis, drug discovery, clinical trial design, supply forecasting, and pharmacovigilance. AI models can integrate signals from genomic sequencing, syndromic surveillance, veterinary alerts, climate data, mobility patterns, and electronic health records to identify risk clusters and support faster triage during outbreaks.

The cumulative impact is strongest when AI is governed by validated datasets, transparent model performance, clinical oversight, and privacy-preserving data sharing. In treatment development, machine learning can accelerate target identification, repurposing screens, protein-structure analysis, and adverse event detection; however, adoption depends on regulatory-grade evidence, bias control, cybersecurity, and interoperability with public health systems.

Key Regional Insights

Asia-Pacific is a critical growth region due to high population density, large livestock systems, biodiversity hotspots, and recurring exposure to vector-borne and foodborne zoonoses. China, India, Japan, South Korea, Australia, and ASEAN countries are investing in surveillance, vaccine capacity, and rapid diagnostics, while treatment access varies widely between advanced urban hospitals and rural outbreak settings. North America benefits from strong public health infrastructure, advanced hospital systems, veterinary surveillance, and active biodefense and pandemic preparedness programs, supporting demand for validated diagnostics, post-exposure prophylaxis, vaccines, antivirals, and antimicrobial stewardship tools.

Latin America faces persistent burdens from arboviruses, leptospirosis, rabies risk, and zoonotic parasitic diseases, with Brazil and Mexico serving as important demand centers for diagnostics, vaccines, and outbreak-ready therapeutics. Europe is shaped by coordinated health security frameworks, antimicrobial stewardship, veterinary regulation, cross-border surveillance, and strong research networks, which encourage evidence-based adoption and high standards for clinical validation.

The Middle East is increasing preparedness due to MERS-CoV experience, pilgrimage-related health security, imported infection risk, and GCC investment in advanced healthcare infrastructure. Africa carries a disproportionate burden for rabies deaths, viral hemorrhagic fever response, and neglected zoonoses, creating urgent need for affordable diagnostics, post-exposure prophylaxis, cold-chain resilience, trained frontline capacity, and regional manufacturing partnerships.

Key Group Insights

ASEAN markets are prioritizing cross-border surveillance, avian influenza readiness, dengue-related care pathways, rabies control, and scalable point-of-care testing as trade, tourism, wildlife interfaces, and dense livestock production increase spillover concerns. The GCC is emphasizing health security, hospital modernization, infection prevention, and regional preparedness after experience with MERS-CoV, making it receptive to high-quality diagnostics, infection control technologies, and stockpile-ready medical countermeasures.

The European Union has a mature regulatory and research environment supported by coordinated health emergency response, veterinary oversight, antimicrobial stewardship, pharmacovigilance, and cross-border data sharing. BRICS countries combine large disease burdens with expanding pharmaceutical manufacturing capacity, rising diagnostic capability, and strategic public health investment, positioning them as important participants in zoonotic disease treatment access, production, and outbreak response.

G7 markets influence global procurement standards through R&D funding, regulatory expectations, preparedness finance, vaccine policy, and support for international health security initiatives. NATO members increasingly view zoonotic outbreaks through a biosecurity and resilience lens that values surveillance, medical countermeasures, interoperable response systems, protected supply chains, and continuity of care during health emergencies.

Key Country Insights

The United States leads in biomedical innovation, pandemic preparedness funding, advanced diagnostics, genomic surveillance, and regulatory pathways for medical countermeasures, while Canada emphasizes integrated public health, zoonotic surveillance, vaccination policy, and antimicrobial stewardship. Mexico and Brazil face significant vector-borne, foodborne, and livestock-associated risks, creating demand for accessible diagnostics, vaccines, post-exposure prophylaxis, and field-deployable treatment support.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong clinical research, public health capacity, veterinary surveillance, and antimicrobial stewardship programs, with Germany and France especially important for pharmaceutical and diagnostics innovation. Russia has substantial scientific capacity and zoonotic monitoring needs across vast ecosystems, while China and India represent large-scale opportunities due to population size, livestock exposure, manufacturing capabilities, emerging diagnostic capacity, and government investment in health security.

Japan, South Korea, and Australia are advanced markets with strong quality expectations, rapid diagnostic adoption, robust public health systems, and regional preparedness roles. Australia’s biosecurity model and zoonotic surveillance capabilities are particularly relevant to animal-human interface management, while Japan and South Korea support innovation through sophisticated healthcare systems, high standards for clinical validation, and strong infectious disease response infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should align product strategy with One Health procurement by demonstrating value across human health, animal health, and public health response. Priority actions include pairing therapies with rapid diagnostics, investing in pathogen-agnostic platforms, building evidence for use in outbreak conditions, and designing products that remain effective in low-resource and cold-chain-constrained environments.

Organizations should strengthen partnerships with public health agencies, veterinary networks, academic laboratories, and regional manufacturers to improve access and trust. Commercial success will depend on antimicrobial stewardship, transparent clinical evidence, flexible supply chains, regulatory preparedness, and the ability to support governments with surveillance-linked treatment pathways rather than isolated products.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in authoritative public sources, including WHO, CDC, WOAH, FAO, national public health agencies, regulatory bodies, peer-reviewed literature, and publicly available government preparedness frameworks. The analysis synthesizes epidemiological burden, policy direction, technology adoption, regional readiness, and treatment access factors.

The methodology emphasizes triangulation across clinical, veterinary, regulatory, and market indicators to identify durable demand signals while avoiding unsupported market claims. Insights are evaluated through a One Health lens, considering disease burden, healthcare infrastructure, diagnostic capacity, vaccine and therapeutic availability, antimicrobial resistance, pharmacovigilance, and outbreak response readiness.

Conclusion

Zoonotic disease treatment is becoming a core component of global health security, driven by recurring outbreaks, antimicrobial resistance, climate-linked vector shifts, ecosystem disruption, and the need for faster, more coordinated response systems. The most resilient market participants will move beyond single-product strategies and build integrated solutions that connect diagnostics, therapeutics, vaccines, surveillance, and access.

As governments and healthcare systems invest in preparedness, organizations that can deliver validated, scalable, and regionally adaptable treatment solutions will be best positioned to capture growth. The future of the market belongs to stakeholders that combine scientific rigor, One Health collaboration, digital intelligence, regulatory readiness, and equitable deployment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Zoonotic Disease Treatment Market, by Therapeutics
7.1. Introduction
7.2. Antibiotics
7.2.1. Beta-Lactams
7.2.2. Macrolides
7.2.3. Tetracyclines
7.3. Antifungals
7.3.1. Azoles
7.3.2. Polyenes
7.4. Antiparasitics
7.4.1. Anthelmintics
7.4.2. Antiprotozoals
7.5. Antivirals
7.5.1. mAb
7.5.2. Nucleoside
7.5.3. Protease Inhibitors
8. Zoonotic Disease Treatment Market, by Vaccine Type
8.1. Introduction
8.2. Preventive Vaccines
8.2.1. Attenuated
8.2.2. Conjugate
8.2.3. mRNA
8.2.4. Recombinant
8.3. Therapeutic Vaccines
8.3.1. Attenuated
8.3.2. Conjugate
8.3.3. mRNA
8.3.4. Recombinant
9. Zoonotic Disease Treatment Market, by Diagnostics
9.1. Introduction
9.2. Imaging
9.2.1. Radiography
9.2.2. Ultrasound
9.3. Molecular Diagnostics
9.3.1. Next Generation Sequencing
9.3.2. PCR
9.4. Point Of Care
9.5. Serology
9.5.1. ELISA
9.5.2. Rapid Test
10. Zoonotic Disease Treatment Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Clinics
10.4. Veterinary Centers
10.5. Research Institutes
11. Zoonotic Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Zoonotic Disease Treatment Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Zoonotic Disease Treatment Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Zoonotic Disease Treatment Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AdvaCare Pharma
16.2. Bharat Biotech International Ltd.
16.3. Bimeda
16.4. Bio-Med Pvt. Ltd.
16.5. Boehringer Ingelheim GmbH
16.6. Ceva Santé Animale
16.7. Chengda Biotechnology Co., Ltd.
16.8. Dechra Pharmaceuticals PLC
16.9. ECO Animal Health Group Plc
16.10. Elanco Animal Health Incorporated
16.11. Endovac Animal Health
16.12. Hester Biosciences Ltd.
16.13. Huvepharma
16.14. IDEXX Laboratories, Inc.
16.15. Inovet Group
16.16. Intas Pharmaceuticals Ltd.
16.17. Kyoritsu Seiyaku Corporation
16.18. Meiji Holdings Co., Ltd.
16.19. Merck & Co., Inc.
16.20. Norbrook Laboratories
16.21. Phibro Animal Health Corporation
16.22. SeQuent Scientific Ltd.
16.23. Vetoquinol S.A.
16.24. Zoetis Inc.
16.25. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BETA-LACTAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BETA-LACTAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BETA-LACTAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AZOLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL AZOLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL AZOLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POLYENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POLYENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POLYENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTHELMINTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ANTHELMINTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ANTHELMINTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ANTIPROTOZOALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ANTIPROTOZOALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ANTIPROTOZOALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NUCLEOSIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NUCLEOSIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NUCLEOSIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL RADIOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RADIOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RADIOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SEROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SEROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SEROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ELISA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ELISA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RAPID TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RAPID TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RAPID TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL VETERINARY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL VETERINARY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL VETERINARY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 144. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 147. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 148. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 149. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 151. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 152. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 153. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 154. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 155. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 157. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. EUROPE ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 191. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 192. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 193. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 194. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 195. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 196. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 197. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 198. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 199. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 200. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 201. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 202. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. AFRICA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 222. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 223. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 224. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 225. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 226. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 227. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 228. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 229. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 230. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 231. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 232. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 233. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. NATO ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 237. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 238. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 239. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 240. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 241. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 242. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 243. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 244. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 245. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 246. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 247. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 248. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. G7 ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 252. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 253. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 254. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 255. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 256. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 257. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 258. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 259. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 260. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 261. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 262. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 263. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. BRICS ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 282. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 283. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 284. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 285. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 286. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 287. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 288. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 289. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 290. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 291. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 292. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 293. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. ASEAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 296. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 297. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 298. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 299. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 300. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 301. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 302. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 303. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 304. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 305. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 306. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 307. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 308. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 309. GCC ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. GLOBAL ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 311. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 313. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 314. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 315. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 316. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 317. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 318. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 319. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 320. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 321. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 322. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 323. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 324. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. CHINA ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 338. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-2032 (USD MILLION)
TABLE 339. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. UNITED STATES ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 341. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTICS, 2017-2032 (USD MILLION)
TABLE 343. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 344. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIFUNGALS, 2017-2032 (USD MILLION)
TABLE 345. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIPARASITICS, 2017-2032 (USD MILLION)
TABLE 346. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY ANTIVIRALS, 2017-2032 (USD MILLION)
TABLE 347. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 348. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY PREVENTIVE VACCINES, 2017-2032 (USD MILLION)
TABLE 349. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY THERAPEUTIC VACCINES, 2017-2032 (USD MILLION)
TABLE 350. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 351. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY IMAGING, 2017-2032 (USD MILLION)
TABLE 352. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 353. JAPAN ZOONOTIC DISEASE TREATMENT MARKET SIZE, BY SEROLOGY, 2017-203

Companies Mentioned

  • AdvaCare Pharma
  • Bharat Biotech International Ltd.
  • Bimeda
  • Bio-Med Pvt. Ltd.
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale
  • Chengda Biotechnology Co., Ltd.
  • Dechra Pharmaceuticals PLC
  • ECO Animal Health Group Plc
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Ltd.
  • Huvepharma
  • IDEXX Laboratories, Inc.
  • Inovet Group
  • Intas Pharmaceuticals Ltd.
  • Kyoritsu Seiyaku Corporation
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Norbrook Laboratories
  • Phibro Animal Health Corporation
  • SeQuent Scientific Ltd.
  • Vetoquinol S.A.
  • Zoetis Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 52.02 Billion
Forecasted Market Value ( USD ) by 2032 $ 88.27 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Therapeutic Vaccines Market - Global Forecast 2026-2032 - Product Image

Therapeutic Vaccines Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Therapeutic Vaccines - Global Strategic Business Report - Product Image

Therapeutic Vaccines - Global Strategic Business Report

  • Report
  • 346 Pages
  • Global
From
Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2026-2034 - Product Image

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2026-2034

  • Report
  • 135 Pages
  • Global
From
Therapeutic Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Therapeutic Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Therapeutic Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Therapeutic Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.